Kreitzer Anatol sold $1.3M of MPLT
Kreitzer Anatol (Chief Discovery Officer) sold 36,284 shares of MapLight Therapeutics, Inc. (MPLT) at an average of $37.09 ($36.13–$38.39, $1.35M total) across 7 trades over 2026-07-15 to 2026-07-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider activity: Kreitzer Anatol, Chief Discovery Officer, sold shares in multiple trades at $36.13 to $38.39 per share, totaling about $1.35M, under a 10b5-1 plan.
Market read
Primarily a sentiment/positioning datapoint; no new business or financial guidance is provided.
What to watch
Traders may over-weight insider sales; without concurrent news on pipeline, trials, or financing, the signal is likely weak.
Background
The article is an SEC Form 4 insider transaction for MapLight Therapeutics, Inc. (MPLT).
Ticker impact
MapLight Therapeutics insider Form 4 shows CDO Kreitzer Anatol sold 36,284 shares in open-market trades for about $1.35M under a 10b5-1 plan.
Low near-term impact; any reaction is likely limited to sentiment and positioning rather than fundamentals.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the article provides no accompanying operational or guidance change.
Market effects
No direct sector read-through; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.
Key entities
- issuerMapLight Therapeutics, Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderKreitzer Anatol
Chief Discovery Officer who executed open-market sales under a 10b5-1 plan.